ClinicalTrials.gg
Drug

Quizartinib clinical trials

Also written AC220, Vanflyta and AC010220.

studies test it
37
open now
7
in phase 3
5
first study started
2007

How each study uses quizartinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the quizartinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
20 Jul 2023 · VANFLYTA · NDA 216993 (FDA, Drugs@FDA)
European Union
6 Nov 2023 · Vanflyta · EMEA/H/C/005910 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Quizartinib
34
Test Product
3
Quizartinib dihydrochloride
2

Brand

Vanflyta
9

Development codes

AC220
19
AC010220
7
ASP2689
4

Studies by the year they started

37 studies that test it; most in 2024 (6)

Studies that test quizartinib, by start year
YearStudies
20071
20113
20122
20131
20141
20164
20171
20184
20194
20205
20211
20221
20231
20246
20251
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
24
Phase 2
16
Phase 3
5

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 22 · Other 15

Daiichi Sankyo (15) · M.D. Anderson Cancer Center (6) · Daiichi Sankyo Co., Ltd. (6) · PETHEMA Foundation (3) · Therapeutic Advances in Childhood Leukemia Consortium (1) · Cardiff University (1) · National Cancer Institute (NCI) (1) · Kura Oncology, Inc. (1)

Often tested with

Tested in the same studies.

Venetoclax (3) · Cytarabine (3) · CPX-351 (2) · Azacitidine (2) · Decitabine (1) · Rufinamide (1) · Efavirenz (1) · Dabigatran (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test quizartinib.

Studies

Open first, then newest update. How each study uses quizartinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 37

See all 37 studies that test quizartinib →

Given beside what is tested · 5 — quizartinib is usual care or a partner of the new treatment

Codes

What other systems call quizartinib · ClinicalTrials.gg INT005514

  • MeSH (NLM) C544967quizartinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 7LA4O6Q0D3QUIZARTINIBConfirmed FDA, NLM, Wikidata
  • Wikidata Q7272714quizartinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C68936QuizartinibOne source FDA
  • DrugBank DB12874One source Wikidata

Also registered as quizartinib dihydrochloride (UNII WK7Q6ZIZ10).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.